Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06977581 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
A Phase 2 study of Asthma, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT06977581: Recruiting Phase 2 study of Asthma, sponsored by Pfizer.
NCT06977581 is a Phase 2 study of Asthma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 252 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06977581, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking their regular maintenance treatment(s) for asthma over the last 12 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants will be involved in this study for about 7.5 months. During this time, they will have 9 visits at the study clinic.
Primary Outcome
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PF-07275315
Study Locations (20)
California
- Antelope Valley Clinical Trials - Lancaster
- NewportNativeMD, Inc. - Newport Beach
- California Medical Research Associates - Northridge
- Allergy and Asthma Associates of Santa Clara Valley Research Center - San Jose
- Allergy & Asthma Clinical Research - Walnut Creek
Illinois
- Christie Clinic - University - Champaign
- Innovo Research - Christie Clinic - Champaign
- Christie Clinic - Windsor - Champaign
Michigan
- North Ingalls Building - Ann Arbor
- University of Michigan - Ann Arbor
New Jersey
- Rutgers, Robert Wood Johnson Medical School - New Brunswick
- Circuit Clinical / Impact Medical Allergy, Asthma & Immunology - Riverdale
Alabama
- Velocity Clinical Research, Mobile - Mobile
Arizona
- Chandler Clinical Trials - Chandler
Colorado
- Colorado ENT & Allergy - Colorado Springs
Georgia
- Cpcc-Research Llc - East Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
What NCT06977581 shows while recruiting
NCT06977581 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06977581 names 20 study sites across 12 states, led by California, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT06977581 about?
NCT06977581 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of...
What is the current status of trial NCT06977581?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2025-05-20. Estimated completion is 2027-05-31.
What conditions does trial NCT06977581 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06977581?
The interventions under investigation include: Placebo (OTHER), PF-07275315 (DRUG).
Who is sponsoring clinical trial NCT06977581?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06977581 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06977581's enrollment target sits among peer trials
252 138th of 374 higher than 237 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI